Akcea Therapeutics Inc. (NASDAQ: AKCA) shares pulled back on Monday after the company announced a big change to its board of directors. With this change, Akcea’s management acknowledges that the company is entering a new phase of commercializing drugs with the global approval and launch of Tegsedi (inotersen).
The company announced that Damien McDevitt, Ph.D. chief business officer (CBO) of Ionis Pharmaceuticals, is joining the Akcea board of directors to replace Ionis founder, board chair and CEO Stanley T. Crooke, M.D., Ph.D., who has resigned from Akcea’s board of directors.
As Ionis’s CBO, McDevitt is responsible for leading the company’s corporate development activities, including business development, competitive intelligence, alliance management investor relations and corporate communications.
Paula Soteropoulos, CEO of Akcea, commented:
We thank Stan for his leadership in founding Akcea and leading it to this key point in our maturation. His impact on Akcea has been immeasurable. Though he is leaving our board, we know he will remain keenly interested in the company’s progress as Ionis is our most important partner and our largest shareholder. We will continue to benefit from his insights as we advance in our mission to bring transformative medicines to patients with unmet medical needs.
Excluding Monday’s move, Akcea has underperformed the broad markets, with the stock up only 9% in the past 52 weeks. However, in just 2018 alone, the stock is up 83.5%.
Shares of Akcea were last seen down about 10% at $28.65, with a consensus analyst price target of $40.50 and a 52-week range of $15.20 to $40.75.
24/7 Wall St.Sponsored: Want to Retire Early? Start Here
Want retirement to come a few years earlier than you’d planned? Orare you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
